Sirolimus for the prevention of in-stent restenosis in a coronary artery.
Marks
Andrew R
AR
Department of Physiology and Cellular Biophysics, Center for Molecular Cardiology, Columbia University College of Physicians and Surgeons, New York, USA.
D003327:Coronary Disease / Q000150:complications / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003331:Coronary Vessels; D048909:Diabetes Complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015335:Molecular Probes; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use*; D015607:Stents
D007166:Immunosuppressive Agents; D015335:Molecular Probes; D020123:Sirolimus